Chugai Pharma USA

Chugai Pharma USA is the United States subsidiary of Chugai Pharmaceutical Co., Ltd., a leading Japanese R&D-based pharmaceutical company and a member of the Roche Group. The company focuses on the clinical development and regulatory approval of innovative therapies discovered by its parent company, particularly in the fields of oncology, immunology, and rare diseases. Chugai is renowned for its proprietary antibody engineering technologies, which have produced blockbuster treatments such as Hemlibra for hemophilia A and Actemra for rheumatoid arthritis. Based in New Jersey, Chugai Pharma USA serves as a critical bridge for bringing Japanese medical innovation to the North American market. The company manages a robust pipeline of biologics and small molecules, leveraging advanced platforms like recycling and sweeping antibodies to address significant unmet medical needs.